通过靶向内皮细胞代谢来调控血管生成：直击引擎而非驱动因素——新视角？
Manipulating Angiogenesis by Targeting Endothelial Metabolism: Hitting the Engine Rather than the Drivers-A New Perspective?
机构信息
Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, University of Leuven, and Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Vlaams Instituut voor Biotechnologie, Leuven, Belgium.
Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, University of Leuven, and Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Vlaams Instituut voor Biotechnologie, Leuven, Belgium
出版信息
Pharmacol Rev. 2016 Jul;68(3):872-87. doi: 10.1124/pr.116.012492.
Excessive angiogenesis (i.e., the formation of new blood vessels) contributes to different pathologies, among them cancer and ocular disorders. Conversely, dysfunction of endothelial cells (ECs) contributes to cardiovascular complications, as is the case in diabetes. Inhibition of pathologic angiogenesis in blinding eye disease and cancer by targeting growth factors such as vascular endothelial growth factor has become an accepted therapeutic strategy. However, recent studies also unveiled the emerging importance of EC metabolism in controlling angiogenesis. In this overview, we will discuss recent insights in the metabolic regulation of angiogenesis, focusing on the best-characterized metabolic pathways, and highlight deregulation of EC metabolism in cancer and diabetes. We will give an outlook on how targeting EC metabolism can be used for blocking pathologic angiogenesis and for normalizing EC dysfunction.
过度的血管生成（即新血管的形成）会导致多种病理，其中包括癌症和眼部疾病。相反，内皮细胞（EC）的功能障碍会导致心血管并发症，如糖尿病。通过针对血管内皮生长因子等生长因子来抑制致盲眼病和癌症中的病理性血管生成已成为一种公认的治疗策略。然而，最近的研究也揭示了 EC 代谢在控制血管生成方面的新重要性。在这篇综述中，我们将讨论血管生成代谢调控的最新见解，重点介绍研究最充分的代谢途径，并强调癌症和糖尿病中 EC 代谢的失调。我们将展望如何针对 EC 代谢来阻断病理性血管生成并使 EC 功能正常化。
Zotero 插件